Kura Oncology (KURA) Institutional Ownership

During the previous two years, 158 institutional investors and hedge funds held shares of Kura Oncology. The most heavily invested institutionals were State Street Corp ($52.15M), Armistice Capital LLC ($48.39M), Suvretta Capital Management LLC ($44.22M), Vanguard Group Inc. ($41.97M), Artal Group S.A. ($40.95M), Deerfield Management Company L.P. Series C ($39.89M), and RA Capital Management L.P. ($38.77M).Learn more on KURA's institutional investors.

Of the 139 institutional investors that purchased Kura Oncology stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($4.45M), BVF Inc. IL ($3.57M), Prosight Management LP ($1.96M), Millennium Management LLC ($1.52M), Suvretta Capital Management LLC ($1.23M), Affinity Asset Advisors LLC ($1.18M), and Deerfield Management Company L.P. Series C ($1.14M).

Institutional investors have bought a total of 31,446,114 shares in the last 24 months. This purchase volume represents approximately $363.89M in transactions.

Of the 66 institutional investors that sold Kura Oncology stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BVF Inc. IL ($3.39M), Suvretta Capital Management LLC ($2.58M), Avoro Capital Advisors LLC ($1.60M), Assenagon Asset Management S.A. ($826.39K), Affinity Asset Advisors LLC ($799.27K), Candriam S.C.A. ($606.77K), and Dimensional Fund Advisors LP ($468.82K).

Institutional investors have sold a total of 12,514,533 shares in the last 24 months. This volume of shares sold represents approximately $178.45M in transactions.